76 results on '"Arcani, R."'
Search Results
2. Assessing the effect of PRP addition to facial micro-lipofilling for patients suffering from Scleroderma: A prospective routine care analysis
- Author
-
Abellan Lopez, M., Philandrianos, C., Daumas, A., Velier, M., Arcani, R., Jouve, E., Jaloux, C., Bertrand, B., Magalon, J., Dignat-George, F., Granel, B., Casanova, D., and Sabatier, F.
- Published
- 2023
- Full Text
- View/download PDF
3. Should we prevent thrombosis related to intravenous immunoglobulin infusions with systematic anticoagulant prophylaxis?
- Author
-
Arcani, R., Grapperon, A.-M., Venton, G., Suchon, P., Verschueren, A., Bas, J., Salort-Campana, E., Attarian, S., and Delmont, E.
- Published
- 2021
- Full Text
- View/download PDF
4. Une splénomégalie fébrile
- Author
-
Dalmas, P., primary, Arcani, R., additional, Nivaggioni, V., additional, André, V., additional, Gayet, S., additional, Chabbert, V., additional, Garrido, V., additional, Camillieri, S., additional, Lavrard, P., additional, Villani, P., additional, and Daumas, A., additional
- Published
- 2023
- Full Text
- View/download PDF
5. POS1417 CATEGORIZATION OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS USING DISEASE ACTIVITY, PATIENT-REPORTED OUTCOMES AND TRANSCRIPTOMIC SIGNATURES
- Author
-
Arcani, R., primary, Jouve, E., additional, Chiche, L., additional, and Jourde-Chiche, N., additional
- Published
- 2023
- Full Text
- View/download PDF
6. Severe renal insufficiency is not an absolute pitfall to autologous stem cell transplantation with BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning regimen
- Author
-
Farnault, L., Venton, G., Pourroy, B., Jourde-Chiche, N., Ivanov, V., Arcani, R., Roche, P., Mercier, C., Colle, J., Fanciullino, R., and Costello, RT
- Published
- 2019
- Full Text
- View/download PDF
7. Assessing the effect of PRP addition to facial micro-lipofilling for patients suffering from Scleroderma: A prospective routine care analysis
- Author
-
Abellan Lopez, M., primary, Philandrianos, C., additional, Daumas, A., additional, Velier, M., additional, Arcani, R., additional, Jouve, E., additional, Jaloux, C., additional, Bertrand, B., additional, Magalon, J., additional, Dignat-George, F., additional, Granel, B., additional, Casanova, D., additional, and Sabatier, F., additional
- Published
- 2022
- Full Text
- View/download PDF
8. High incidence of CDA deficiency in patients with hematological malignancies: perspectives and therapeutic implications
- Author
-
Donnette, M., Ciccolini, J., Pissier, C., Costello, R., Duffaud, F., Salas, S., Farnault, L., Tichadou, A., Arcani, R., Jarrot, P.A., Ouafik, L.H., Venton, G., Fanciullino, R., Ouafik, L'Houcine, Simulation and Modeling of Adaptive Response for Therapeutics in Cancer (SMARTc), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Transfert d'Oncologie Biologique [Hôpital Nord - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Service d’Oncologie Médicale [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Médecine interne et immunologie clinique [Hôpital de la Conception - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Méthodes computationnelles pour la prise en charge thérapeutique en oncologie : Optimisation des stratégies par modélisation mécaniste et statistique (COMPO), Inria Sophia Antipolis - Méditerranée (CRISAM), and Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre de Recherche en Cancérologie de Marseille (CRCM)
- Subjects
Oncology ,medicine.medical_specialty ,[SDV]Life Sciences [q-bio] ,MEDLINE ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Humans ,Medicine ,In patient ,ComputingMilieux_MISCELLANEOUS ,B cell ,030304 developmental biology ,0303 health sciences ,business.industry ,Incidence ,Incidence (epidemiology) ,Hematology ,Cytidine deaminase ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,3. Good health ,Leukemia ,medicine.anatomical_structure ,Hematologic Neoplasms ,030220 oncology & carcinogenesis ,High incidence ,business - Abstract
International audience
- Published
- 2021
9. Anticorps anti-NuMA : associations cliniques et impact sur le phénotype de patients atteints de syndrome de Sjögren primitif et de lupus érythémateux systémique
- Author
-
Arcani, R., primary, Bertin, D., additional, Bardin, N., additional, Jean, R., additional, Mazodier, K., additional, Jarrot, P.A., additional, and Kaplanski, G., additional
- Published
- 2021
- Full Text
- View/download PDF
10. Un effet indésirable rare de l’amiodarone : la neuropathie optique
- Author
-
Arcani, R., Pellerey, M., Rouby, F., Gobin, N., Scapin, J., Chagny, M., Arnould, T., Ambrosi, P., Gayet, S., Micallef, J., Villani, P., and Daumas, A.
- Published
- 2019
- Full Text
- View/download PDF
11. Principle of the proper use of drugs and non-drug therapies
- Author
-
Bouhanick, B., Doucet, Jean, Zulfiqar, A.A., Arcani, R., Daumas, Aurélie, Villani, Patrick, Trouvin, A.P., Perrot, S., Benevent, J., Montastruc, J.L., Orlikowski, D., Puigrenier, S., Yelnik, C., Lambert, M., Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital de la Timone [CHU - APHM] (TIMONE), CHU Rouen, Normandie Université (NU), Hôpital Ambroise Paré [AP-HP], AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Hôpital Raymond Poincaré [AP-HP], Centre Hospitalier Universitaire de Lille (CHU de Lille), CHU Toulouse [Toulouse], Université de Toulouse, Faculté de Médecine, and COMBE, Isabelle
- Subjects
[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Drug Therapy ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Humans ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,[SDV.MP.PAR] Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2018
12. MON-172 SURVIVAL OF PATIENTS WITH RENAL TRANSPLANTATION IN THE BOLIVIAN UNIVERSITY HOSPITAL CLINICS
- Author
-
CASTRO ÑUCO, I.M., primary, Mamani Choquetarqui, W.E., additional, Quispe Marca, E., additional, Segura Herbas, V.D., additional, Lopez Arcani, R., additional, and Fernandez Loza, F., additional
- Published
- 2019
- Full Text
- View/download PDF
13. Hematopoietic reconstitution after autologous hematopoietic stem cell transplantation: do CD45 (+) CD34 (+) CD38 (−) progenitors really matter in real life?
- Author
-
Venton, G., primary, Suchon, P., additional, Colle, J., additional, Baier, C., additional, Sanderson, F., additional, Poullin, P., additional, Ivanov, V., additional, Mercier, C., additional, Farnault, L., additional, Roche, P., additional, Arcani, R., additional, Fanciullino, R., additional, Brunet, C., additional, Philip, P.J.M., additional, and Costello, R., additional
- Published
- 2018
- Full Text
- View/download PDF
14. Pneumocystose en médecine interne en dehors d’une co-infection par le VIH
- Author
-
Dalma, J.B., primary, Arcani, R., additional, Koubi, M., additional, Rossi, P., additional, Kaplanski, G., additional, Bernit, E., additional, Veit, V., additional, Schleinitz, N., additional, Harlé, R., additional, Albanese, J., additional, and Papazian, L., additional
- Published
- 2017
- Full Text
- View/download PDF
15. CATEGORIZATION OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS USING DISEASE ACTIVITY, PATIENT-REPORTED OUTCOMES AND TRANSCRIPTOMIC SIGNATURES.
- Author
-
Arcani, R., Jouve, E., Chiche, L., and Jourde-Chiche, N.
- Published
- 2023
- Full Text
- View/download PDF
16. Principle of the proper use of drugs and non-drug therapies,Principe du bon usage du médicament et des thérapeutiques non médicamenteuses
- Author
-
Bouhanick, B., Doucet, J., Zulfiqar, A. -A, Arcani, R., Daumas, A., Villani, P., Anne-Priscille TROUVIN, Perrot, S., Benevent, J., Montastruc, J. -L, Orlikowski, D., Puigrenier, S., Yelnik, C., and Lambert, M.
17. Hematopoietic reconstitution after autologous hematopoietic stem cell transplantation: do CD45 (+) CD34 (+) CD38 (−) progenitors really matter in real life?
- Author
-
Baier, C., Ivanov, V., Farnault, L., Roche, P., Arcani, R., Brunet, C., Philip, P.J.M., Venton, G., Colle, J., Costello, R., Sanderson, F., Poullin, P., Mercier, C., Suchon, P., and Fanciullino, R.
- Subjects
- *
AUTOTRANSFUSION of blood , *HEMATOPOIETIC stem cell transplantation , *PROGENITOR cells - Published
- 2018
- Full Text
- View/download PDF
18. Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey.
- Author
-
Jarrot PA, Mirouse A, Ottaviani S, Cadiou S, Salmon JH, Liozon E, Parreau S, Michaud M, Terrier B, Gavand PE, Trefond L, Lavoiepierre V, Keraen J, Rekassa D, Bouldoires B, Weitten T, Roche D, Poulet A, Charpin C, Grobost V, Hermet M, Pallure M, Wackenheim C, Karkowski L, Grumet P, Rogier T, Belkefi N, Pestre V, Broquet E, Leurs A, Gautier S, Gras V, Gilet P, Holubar J, Sivova N, Schleinitz N, Durand JM, Castel B, Petrier A, Arcani R, Gramont B, Guilpain P, Lepidi H, Weiller PJ, Micallef J, Saadoun D, and Kaplanski G
- Subjects
- Adult, Humans, Middle Aged, COVID-19 Vaccines adverse effects, Ad26COVS1, BNT162 Vaccine, ChAdOx1 nCoV-19, Vaccination adverse effects, Giant Cell Arteritis epidemiology, Polymyalgia Rheumatica epidemiology, COVID-19 epidemiology, COVID-19 prevention & control
- Abstract
We conducted a national in-depth analysis including pharmacovigilance reports and clinical study to assess the reporting rate (RR) and to determine the clinical profile of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in COVID-19-vaccinated individuals. First, based on the French pharmacovigilance database, we estimated the RR of PMR and GCA cases in individuals aged over 50 who developed their initial symptoms within one month of receiving the BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines. We then conducted a nationwide survey to gather clinical profiles, therapeutic management, and follow-up data from individuals registered in the pharmacovigilance study. A total of 70 854 684 COVID-19 vaccine doses were administered to 25 260 485 adults, among which, 179 cases of PMR (RR 7. 1 cases/1 000 000 persons) and 54 cases of GCA (RR 2. 1 cases/1 000 000 persons) have been reported. The nationwide survey allowed the characterization of 60 PMR and 35 GCA cases. Median time to the onset of first symptoms was 10 (range 2-30) and 7 (range 2-25) days for PMR and GCA, respectively. Phenotype, GCA-related ischemic complications and -large vessel vasculitis as well as therapeutic management and follow-up seemed similar according to the number of vaccine shots received and when compared to the literature data of unvaccinated population. Although rare, the short time between immunization and the onset of first symptoms of PMR and GCA suggests a temporal association. Physician should be aware of this potential vaccine-related phenomenon.
- Published
- 2024
- Full Text
- View/download PDF
19. [Geriatric failure to thrive: between illusory diagnosis and clinical reality].
- Author
-
Bretelle F, Nicot P, Arcani R, Horowitz T, Comon M, Garrido V, Daumas A, and Bonin-Guillaume S
- Subjects
- Humans, Aged, 80 and over, Male, Endocarditis diagnosis, Female, Failure to Thrive etiology
- Abstract
The geriatric failure to thrive, a controversial French concept not present in the international literature, was first characterized by Jean Carrié in 1956. It is described as a process of aging and physical and psychological decline associated with advanced age, manifesting as a pronounced overall deterioration. In this case report, we present the case of an 88-year-old patient, admitted to a general medicine service for geriatric failure to thrive, whose management eventually leads to the diagnosis of endocarditis with digestive cancer complicated by a characterized depressive episode. This case prompts us to consider the geriatric failure to thrive with extreme caution and challenges the legitimacy of such a diagnosis in the context of an aging population and the progress of medical sciences.
- Published
- 2024
- Full Text
- View/download PDF
20. Persistent COVID-19: A Case Report of an Immunocompromised Patient and a Literature Review.
- Author
-
Bekkaoui S, Venton G, Bretelle F, Garrido V, Chabbert V, Gayet S, Dalmas P, Tichadou A, Jarrot PA, Villani P, Daumas A, and Arcani R
- Subjects
- Humans, Male, Bronchoalveolar Lavage Fluid virology, COVID-19 Serotherapy, Middle Aged, Immunization, Passive, Sputum, COVID-19 immunology, COVID-19 diagnosis, COVID-19 complications, Immunocompromised Host, SARS-CoV-2 isolation & purification, SARS-CoV-2 immunology, Lymphoma, Mantle-Cell diagnosis
- Abstract
Introduction: Immunocompromised patients can show prolonged shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and persistent symptoms, which is called persistent COVID-19., Case Presentation: We report a case of an immunocompromised patient who was treated for mantle cell lymphoma and was suffering from B-cell depletion. The patient developed persistent COVID-19, which was confirmed by real-time polymerase chain reaction (RT-PCR) tests in only sputum and bronchoalveolar fluid which remained positive for at least 112 days. The patient was successfully treated with SARS-CoV-2 convalescent plasma., Conclusion: It could be of interest to investigate the RT-PCR results of SARS-CoV-2 in sputum/bronchoalveolar lavage samples from immunocompromised patients with unexplained pneumonia., (© 2024 S. Karger AG, Basel.)
- Published
- 2024
- Full Text
- View/download PDF
21. [Febrile splenomegaly].
- Author
-
Dalmas P, Arcani R, Nivaggioni V, André V, Gayet S, Chabbert V, Garrido V, Camillieri S, Lavrard P, Villani P, and Daumas A
- Subjects
- Humans, Fever diagnosis, Fever etiology, Splenomegaly diagnosis, Splenomegaly etiology, Lymphohistiocytosis, Hemophagocytic
- Published
- 2023
- Full Text
- View/download PDF
22. [Medication reconciliation: Interests and limits].
- Author
-
Correard F, Arcani R, Montaleytang M, Nakache J, Berard C, Couderc AL, Villani P, and Daumas A
- Subjects
- Humans, Medication Errors prevention & control, Hospitalization, Patient Discharge, Patient Admission, Medication Reconciliation, Pharmacists
- Abstract
Admission to hospital is a critical transition point for the continuity of care in medication management. Medication reconciliation can identify and resolve errors due to inaccurate medication histories. The practice of medication reconciliation is securing for the patient because of the medication errors detected with significant clinical impact. Its implementation must comply with the recommendations of the French National Authority for Health (HAS) and its deployment is now integrated into the contract for improving the quality and efficiency of care (CAQES). However, although it allows to intercept medication errors, its impact on the length of hospitalization, the rate of readmission and/or death following discharge seems limited. Given the limited human resources to carry out this time-consuming activity, patient prioritization should be considered. Studies on the fate of patients and on the medico-economic issues are also necessary in order to make this activity sustainable., (Copyright © 2023 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
23. Anti-Jo-1 autoantibodies: biomarkers of severity and evolution of the disease in antisynthetase syndrome.
- Author
-
Arcani R, Rey L, Mazziotto A, Bertin D, Kaplanski G, Jarrot PA, Lafforgue P, Venton G, Heim X, Villani P, Mège JL, Brodovitch A, and Bardin N
- Subjects
- Humans, Biomarkers, Retrospective Studies, Autoantibodies, Myositis
- Abstract
Background: Anti-Jo-1 autoantibodies represent essential markers in the diagnosis of antisynthetase syndrome (ASS). In this retrospective study, we aimed to investigate whether their concentrations and fluctuations could both respectively reflect the severity and evolution of ASS., Methods: Between 2015 and 2020, clinical and biological features of ASS patients with at least one positive measure of anti-Jo-1 autoantibody were collected. At each serum sampling, we assessed myositis activity by using the Myositis Intention to Treat Activities Index (MITAX) and compared anti-Jo-1 concentrations with ASS severity, anti-Jo-1 concentrations between patients with and without active disease, and changes in anti-Jo-1 concentrations with disease activity., Results: Forty-eight patients with ASS had at least one positive determination of anti-Jo-1 concentration. Among them, twenty-nine patients had at least two determinations of anti-Jo-1 autoantibody in their follow-up. We showed that these autoantibody concentrations were significantly correlated with MITAX (r = 0.4, p = 0.03) and creatine kinase concentration (r = 0.34, p = 0.002) and that they were significantly higher in patients with active disease than in those with inactive disease (91.7 IU/L vs 44.4 IU/L, p = 0.016). During follow-up, we found a significant correlation between fluctuations of anti-Jo-1 autoantibody concentrations and MITAX score (r = 0.7, p < 0.0001)., Conclusion: Our results suggest that anti-Jo-1 autoantibody concentration could be a predictive marker of the severity and evolution of ASS and show that their quantification could represent a precious tool for disease monitoring and for improving the therapeutic management of ASS patients., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
24. Therapy-related myeloid neoplasms after 177Lu-DOTATATE therapy for metastatic neuroendocrine neoplasia: CPX-351 consolidated by allogeneic stem cells transplantation as applicable therapeutic strategy.
- Author
-
Berton G, Arcani R, Tichadou A, Farnault L, Roche P, Colle J, Ivanov V, Mercier C, Couderc AL, Costello R, Taïeb D, and Venton G
- Subjects
- Humans, Daunorubicin therapeutic use, Cytarabine therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neoplasms drug therapy, Hematopoietic Stem Cell Transplantation adverse effects, Leukemia, Myeloid, Acute drug therapy
- Published
- 2023
- Full Text
- View/download PDF
25. Categorization of patients with systemic lupus erythematosus using disease activity, patient-reported outcomes, and transcriptomic signatures.
- Author
-
Arcani R, Jouve E, Chiche L, and Jourde-Chiche N
- Subjects
- Humans, Quality of Life, Patient Reported Outcome Measures, Interferons, Severity of Illness Index, Transcriptome, Lupus Erythematosus, Systemic diagnosis
- Abstract
Objective: Patients with systemic lupus erythematosus (SLE) display symptoms that are not always related to disease activity and may distort clinical trial results. Recently, a clinical categorization based on the presence of type 1 (inflammatory manifestations) and/or type 2 (widespread pain, fatigue, depression) symptoms has been proposed in SLE. Our aim was to develop a type 2 score derived from the Short-Form health survey (SF-36) to categorize SLE patients and to compare immunological and transcriptomic profiles between groups., Method: Seventeen items from the SF-36 were selected to build a type 2 score for 50 SLE patients (100 visits; LUPUCE cohort), and the SLEDAI was used to define type 1 symptoms. Patients were categorized into four groups: minimal (no symptoms), type 1, type 2, and mixed (both type 1 and type 2 symptoms). Clinical, immunological, and transcriptomic profiles were compared between the groups., Results: Type 2 scores ranged from 0 to 31, with a cutoff value of 14 (75th percentile). The sample categorization was minimal in 39%, type 1 in 37%, and type 2 in 9%, and mixed in 15%. Type 2 patients were older than minimal patients and had a longer disease duration than type 1 and mixed patients. Immunological data and modular interferon signatures did not differ between the groups., Conclusion: Patients with SLE can be categorized into four clinical groups using the SLEDAI score and our SF-36-derived type 2 score. This categorization is non-redundant with immunological or transcriptomic profiles and could prove useful to stratify patients in clinical trials. Key Points • A score derived from selected items of the SF-36 can be used to identify SLE patients with type 2 symptoms according to the Duke University categorization. • Using the SLEDAI and this type 2 score, SLE patients can be categorized into four clinical groups. • This categorization is not related to immunological activity or blood transcriptome profiles (and not to the interferon signature in particular). • This categorization could be useful in the daily care of patients as well as in clinical trials, for upstream patient stratification or for the interpretation of results., (© 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).)
- Published
- 2023
- Full Text
- View/download PDF
26. Tocilizumab versus anakinra in COVID-19: results from propensity score matching.
- Author
-
Arcani R, Correard F, Suchon P, Kaplanski G, Jean R, Cauchois R, Leprince M, Arcani V, Seguier J, De Sainte Marie B, Andre B, Koubi M, Rossi P, Gayet S, Gobin N, Garrido V, Weiland J, Jouve E, Couderc AL, Villani P, and Daumas A
- Subjects
- Humans, Male, Aged, SARS-CoV-2, Interleukin 1 Receptor Antagonist Protein therapeutic use, Propensity Score, Retrospective Studies, COVID-19 Drug Treatment, Oxygen, COVID-19
- Abstract
Background: Tocilizumab and anakinra are anti-interleukin drugs to treat severe coronavirus disease 2019 (COVID-19) refractory to corticosteroids. However, no studies compared the efficacy of tocilizumab versus anakinra to guide the choice of the therapy in clinical practice. We aimed to compare the outcomes of COVID-19 patients treated with tocilizumab or anakinra., Methods: Our retrospective study was conducted in three French university hospitals between February 2021 and February 2022 and included all the consecutive hospitalized patients with a laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection assessed by RT-PCR who were treated with tocilizumab or anakinra. A propensity score matching was performed to minimize confounding effects due to the non-random allocation., Results: Among 235 patients (mean age, 72 years; 60.9% of male patients), the 28-day mortality (29.4% vs. 31.2%, p = 0.76), the in-hospital mortality (31.7% vs. 33.0%, p = 0.83), the high-flow oxygen requirement (17.5% vs. 18.3%, p = 0.86), the intensive care unit admission rate (30.8% vs. 22.2%, p = 0.30), and the mechanical ventilation rate (15.4% vs. 11.1%, p = 0.50) were similar in patients receiving tocilizumab and those receiving anakinra. After propensity score matching, the 28-day mortality (29.1% vs. 30.4%, p = 1) and the rate of high-flow oxygen requirement (10.1% vs. 21.5%, p = 0.081) did not differ between patients receiving tocilizumab or anakinra. Secondary infection rates were similar between the tocilizumab and anakinra groups (6.3% vs. 9.2%, p = 0.44)., Conclusion: Our study showed comparable efficacy and safety profiles of tocilizumab and anakinra to treat severe COVID-19., Competing Interests: GK has received from ROCHE-CHUGAI Research Grants <€20,000 and fees from Sobi France for scientific presentations <€4,000 and participated in a SOBI Advisory Board on COVID unpaid and an OLATEC Monitoring Board unpaid. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Arcani, Correard, Suchon, Kaplanski, Jean, Cauchois, Leprince, Arcani, Seguier, De Sainte Marie, Andre, Koubi, Rossi, Gayet, Gobin, Garrido, Weiland, Jouve, Couderc, Villani and Daumas.)
- Published
- 2023
- Full Text
- View/download PDF
27. Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology.
- Author
-
Combaluzier S, Quessada J, Abbou N, Arcani R, Tichadou A, Gabert J, Costello R, Loosveld M, Venton G, and Berda-Haddad Y
- Subjects
- Humans, Mutation genetics, Molecular Biology, Myeloproliferative Disorders diagnosis, Myeloproliferative Disorders genetics, Polycythemia Vera diagnosis, Polycythemia Vera genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics
- Abstract
Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell-derived disorders characterized by uncontrolled proliferation of differentiated myeloid cells. Two main groups of MPN, BCR::ABL1 -positive (Chronic Myeloid Leukemia) and BCR::ABL1 -negative (Polycythemia Vera, Essential Thrombocytosis, Primary Myelofibrosis) are distinguished. For many years, cytomorphologic and histologic features were the only proof of MPN and attempted to distinguish the different entities of the subgroup BCR::ABL1 -negative MPN. World Health Organization (WHO) classification of myeloid neoplasms evolves over the years and increasingly considers molecular abnormalities to prove the clonal hematopoiesis. In addition to morphological clues, the detection of JAK2, MPL and CALR mutations are considered driver events belonging to the major diagnostic criteria of BCR::ABL1 -negative MPN. This highlights the preponderant place of molecular features in the MPN diagnosis. Moreover, the advent of next-generation sequencing (NGS) allowed the identification of additional somatic mutations involved in clonal hematopoiesis and playing a role in the prognosis of MPN. Nowadays, careful cytomorphology and molecular biology are inseparable and complementary to provide a specific diagnosis and to permit the best follow-up of these diseases.
- Published
- 2023
- Full Text
- View/download PDF
28. "True" Antiphospholipid Syndrome in COVID-19: Contribution of the Follow-up of Antiphospholipid Autoantibodies.
- Author
-
Arcani R, Cauchois R, Suchon P, Weber S, Jean R, Jarrot PA, Rey L, Venton G, Koubi M, Muller R, Bertin D, Mège JL, Kaplanski G, and Bardin N
- Subjects
- Humans, Antibodies, Antiphospholipid, Follow-Up Studies, beta 2-Glycoprotein I, Autoantibodies, Antiphospholipid Syndrome complications, COVID-19
- Abstract
Competing Interests: None declared.
- Published
- 2023
- Full Text
- View/download PDF
29. Adipose Tissue and Adipose-Tissue-Derived Cell Therapies for the Treatment of the Face and Hands of Patients Suffering from Systemic Sclerosis.
- Author
-
Coulange Zavarro A, Velier M, Arcani R, Abellan Lopez M, Simoncini S, Benyamine A, Gomes De Pinho Q, Coatmeur R, Wang J, Xia J, Barone L, Casanova D, Dignat-George F, Sabatier F, Granel B, Magalon J, and Daumas A
- Abstract
Adipose tissue is recognized as a valuable source of cells with angiogenic, immunomodulatory, reparative and antifibrotic properties and emerged as a therapeutic alternative for the regeneration and repair of damaged tissues. The use of adipose-tissue-based therapy is expanding in autoimmune diseases, particularly in Systemic Sclerosis (SSc), a disease in which hands and face are severely affected, leading to disability and a decrease in quality of life. Combining the advantage of an abundant supply of fat tissue and a high abundance of stem/stromal cells, fat grafting and adipose tissue-derived cell-based therapies are attractive therapeutic options in SSc. This review aims to synthesize the evidence to determine the effects of the use of these biological products for face and hands treatment in the context of SSc. This highlights several points: the need to use relevant effectiveness criteria taking into account the clinical heterogeneity of SSc in order to facilitate assessment and comparison of innovative therapies; second, it reveals some impacts of the disease on fat-grafting success; third, an important heterogeneity was noticed regarding the manufacturing of the adipose-derived products and lastly, it shows a lack of robust evidence from controlled trials comparing adipose-derived products with standard care.
- Published
- 2023
- Full Text
- View/download PDF
30. Characteristics of JAK2 unmutated erythrocytosis: Distinctive traits between polycythemia vera and non-polycythemia vera patients.
- Author
-
Ernest V, Abbou N, Tichadou A, Arcani R, and Venton G
- Subjects
- Humans, Mutation, Phenotype, Janus Kinase 2 genetics, Polycythemia genetics, Polycythemia Vera genetics
- Abstract
Competing Interests: Declaration of Competing Interest None.
- Published
- 2023
- Full Text
- View/download PDF
31. Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1 -Negative Myeloproliferative Neoplasm.
- Author
-
Abbou N, Piazzola P, Gabert J, Ernest V, Arcani R, Couderc AL, Tichadou A, Roche P, Farnault L, Colle J, Ouafik L, Morange P, Costello R, and Venton G
- Subjects
- Humans, Calreticulin genetics, Calreticulin metabolism, Molecular Biology, Receptors, Thrombopoietin genetics, Receptors, Thrombopoietin metabolism, Myeloproliferative Disorders diagnosis, Myeloproliferative Disorders genetics, Myeloproliferative Disorders therapy, Polycythemia Vera genetics, Thrombocythemia, Essential genetics
- Abstract
BCR::ABL1 -negative myeloproliferative neoplasms (MPNs) include three major subgroups-polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)-which are characterized by aberrant hematopoietic proliferation with an increased risk of leukemic transformation. Besides the driver mutations, which are JAK2, CALR, and MPL , more than twenty additional mutations have been identified through the use of next-generation sequencing (NGS), which can be involved with pathways that regulate epigenetic modifications, RNA splicing, or DNA repair. The aim of this short review is to highlight the impact of molecular biology on the diagnosis, prognosis, and therapeutic management of patients with PV, ET, and PMF.
- Published
- 2022
- Full Text
- View/download PDF
32. Anti-cardiolipin IgG autoantibodies associate with circulating extracellular DNA in severe COVID-19.
- Author
-
Bertin D, Brodovitch A, Lopez A, Arcani R, Thomas GM, Beziane A, Weber S, Babacci B, Heim X, Rey L, Leone M, Mege JL, and Bardin N
- Subjects
- Antibodies, Anticardiolipin, Antibodies, Antiphospholipid, Autoantibodies, Humans, Immunoglobulin A, Immunoglobulin G, Immunoglobulin M, Retrospective Studies, SARS-CoV-2, Antiphospholipid Syndrome, COVID-19, Cell-Free Nucleic Acids
- Abstract
Whereas the detection of antiphospholipid autoantibodies (aPL) in COVID-19 is of increasing interest, their role is still unclear. We analyzed a large aPL panel in 157 patients with COVID-19 according to the disease severity. We also investigated a potential association between aPL and extracellular DNA (exDNA, n = 85) or circulating markers of neutrophil extracellular traps (NET) such as citrullinated histones H3 (CitH3, n = 49). A total of 157 sera of patients infected by SARS-CoV-2 were collected. A large aPL panel including lupus anticoagulant, anti-cardiolipin and anti-beta-2 glycoprotein I (IgG, IgM and IgA), anti-phosphatidylethanolamine IgA, anti-prothrombin (IgG and IgM) was retrospectively analyzed according to the disease severity. We found a total aPL prevalence of 54.8% with almost half of the cases having aCL IgG. Within an extended panel of aPL, only aCL IgG were associated with COVID-19 severity. Additionally, severe patients displayed higher CitH3 levels than mild patients. Interestingly, we highlighted a significant association between the levels of aCL IgG and exDNA only in aCL positive patients with severe disease. In conclusion, we showed a significant link between aPL, namely aCL IgG, and circulating exDNA in patients with severe form of COVID-19, that could exacerbate the thrombo-inflammatory state related to disease severity., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
33. Factors associated with dexamethasone efficacy in COVID-19. A retrospective investigative cohort study.
- Author
-
Arcani R, Cauchois R, Suchon P, Jean R, Jarrot PA, Gomes De Pinho Q, Dalmas JB, Jean E, Andre B, Veit V, Koubi M, and Kaplanski G
- Subjects
- Anti-Bacterial Agents therapeutic use, Cohort Studies, Dexamethasone therapeutic use, Humans, Retrospective Studies, SARS-CoV-2, COVID-19 Drug Treatment
- Abstract
Dexamethasone has demonstrated efficacy in reducing mortality in COVID-19. However, its practical use is badly defined. We aimed to investigate factors associated with dexamethasone efficacy in real life. Our retrospective study was conducted in two university hospitals between September and November 2020 and included all the consecutive hospitalized patients with a laboratory-confirmed SARS-CoV-2 infection assessed by RT-PCR, treated with intravenous dexamethasone (6 mg/day). Among 111 patients, 10.6% necessitated a transfer into the intensive care unit (ICU) and the 28-day mortality rate was 17.1%. The 28-day mortality rate was significantly lower in patients who demonstrated improvement at 48 h (hazard ratio [HR]: 0.17, 95% confidence interval [CI]: 0.04-0.78, p = 0.02) and 96 h (HR: 0.07, 95% CI: 0.02-0.31, p = 0.0005) after dexamethasone initiation. Apart from well-known risk factors (age, hypertension, active cancer, severe lesions on chest computed tomography [CT] scan), we found that a high viral load in nasopharyngeal swab (Cycle threshold <30) at dexamethasone initiation was associated with higher 28-day mortality (66.6% vs. 36.7%, p = 0.03). Patients who did not receive antibiotics at dexamethasone initiation had a higher rate of transfer into the ICU (55.6% vs. 23.5%, p = 0.045) with a trend towards higher mortality in case of severe or critical lesions on CT scan (75.0% vs. 25.0%, p = 0.053). Patients who did not improve within 2-4 days after steroid initiation have a bad prognosis and should receive additional anti-inflammatory drugs. Our data suggest better efficacy of dexamethasone in patients with a low or negative viral load, receiving broad-spectrum antibiotics., (© 2022 Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
34. Functional status in older patients with cancer.
- Author
-
Couderc AL, Suchon P, Saliba-Serre B, Rey D, Nouguerede E, Arcani R, Farnault L, Daumas A, Courcier A, Duffaud F, Salas S, Barlesi F, Greillier L, Costello R, Venton G, and Villani P
- Subjects
- Aged, Aged, 80 and over, Cohort Studies, Functional Status, Geriatric Assessment methods, Humans, Male, Activities of Daily Living, Neoplasms epidemiology
- Abstract
Background: Functional Status (FS) is an important domain in Comprehensive Geriatric Assessment (CGA) and is most often evaluated using the Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) scales separately., Method and Objectives: This secondary analysis of a previous prospective cohort study was conducted between September 2015 and May 2018 at Marseille University Hospital, France, on 613 cancer outpatients aged ≥70 years. The first objective of this study was to determine the prevalence of FS impairment in older outpatients with cancer using a combination of the information collected with the ADL and short IADL scales. Our second objective was to describe the potential impact of this combined FS on three-month unplanned hospitalizations and three-month mortality in this population., Results: The median age was 81 years and 61.2% were men. The most common types of tumours were lung and thoracic (22.3%). Concerning FS, 255 patients (41.6%) had unimpaired ADL-IADL, 131 patients (21.4%) had IADL impairment, 38 patients (6.2%) had ADL impairment, and 189 patients (30.8%) had impaired ADL-IADL. In the multivariate Cox analysis, metastatic stage (adjusted Hazard Ratio (aHR) = 1.79; 95% CI [1.14-2.80]) and impaired ADL-IADL (aHR = 3.46; 95% CI [1.89-6.33]) were independently associated with three-month mortality. In the logistic regression model, impaired ADL-IADL (adjusted Odd ratio (aOR) = 3.64; 95% CI [1.84-7.20]) was the only factor independently associated with three-month unplanned hospitalizations., Interpretation: The combined use of the ADL and IADL scales to evaluate functional status in older patients with cancer is of significant prognostic value regarding the risks of three-month unplanned hospitalizations and mortality., Competing Interests: Declaration of Competing Interest None of the authors have any conflicts of interest to disclose., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
35. Combining systemic and locally applied cellular therapies for the treatment of systemic sclerosis.
- Author
-
Velier M, Daumas A, Simoncini S, Arcani R, Magalon J, Benyamine A, Granel B, Dignat George F, Chabannon C, and Sabatier F
- Subjects
- Adipose Tissue, Humans, Transplantation, Autologous, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells, Scleroderma, Systemic complications, Scleroderma, Systemic therapy
- Abstract
Systemic sclerosis (SSc) is a complex autoimmune disease characterized by a functional and structural alteration of the microvascular network associated with cutaneous and visceral fibrosis lesions. Conventional therapies are based on the use of immunomodulatory molecules and symptomatic management but often prove to be insufficient, particularly for patients suffering from severe and rapidly progressive forms of the disease. In this context, cellular therapy approaches could represent a credible solution with the goal to act on the different components of the disease: the immune system, the vascular system and the extracellular matrix. The purpose of this review is to provide an overview of the cellular therapies available for the management of SSc. The first part will focus on systemically injected therapies, whose primary effect is based on immunomodulatory properties and immune system resetting, including autologous hematopoietic stem cell transplantation and intravenous injection of mesenchymal stem cells. The second part will discuss locally administered regenerative cell therapies, mainly derived from adipose tissue, developed for the management of local complications as hand and face disabilities., (© 2021. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2022
- Full Text
- View/download PDF
36. Persistent IgG anticardiolipin autoantibodies are associated with post-COVID syndrome.
- Author
-
Bertin D, Kaphan E, Weber S, Babacci B, Arcani R, Faucher B, Ménard A, Brodovitch A, Mege JL, and Bardin N
- Subjects
- Autoantibodies, Female, Humans, Immunoglobulin G, Middle Aged, SARS-CoV-2, Post-Acute COVID-19 Syndrome, Antibodies, Anticardiolipin, COVID-19 complications
- Abstract
Persistence of various symptoms in patients who have recovered from coronavirus disease 2019 (COVID-19) was recently defined as 'long COVID' or 'post-COVID syndrome' (PCS). This article reports a case of a 58-year-old woman who, although recovering from COVID-19, had novel and persistent symptoms including neurological complications that could not be explained by any cause other than PCS. In addition to a low inflammatory response, persistence of immunoglobulin G anticardiolipin autoantibody positivity and eosinopenia were found 1 year after acute COVID-19 infection, both of which have been defined previously as independent factors associated with the severity of COVID-19. The pathophysiological mechanism of PCS is unknown, but the possibility of persistence of the virus, especially in the nervous system, could be suggested with a post-infectious inflammatory or autoimmune reaction., Competing Interests: Declaration of Competing Interest None declared., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
37. Relevance of systematic anti-nuclear antibodies testing after obstetrical complications.
- Author
-
Koubi M, Rossi P, Arcani R, Gomes De Pihno Q, Chau C, Blanc J, Grosdidier C, Guervilly C, Bretelle F, and Bernard-Guervilly F
- Subjects
- Adult, Antibodies, Antiphospholipid blood, Female, Humans, Pregnancy, Pregnancy Outcome, Retrospective Studies, Antibodies, Antinuclear blood, Antiphospholipid Syndrome diagnosis, Autoimmune Diseases diagnosis, Biomarkers blood, Pregnancy Complications diagnosis, Thrombophilia diagnosis
- Abstract
Adverses pregnancy outcomes are commonly encountered with autoimmune disease (AID). Although anti-nuclear antibodies (ANA) are often present several years before AID diagnosis, the importance of ANA testing has not been evaluated in this context. The objective of this study was to determine if ANA discovery after obstetrical complications is associated with a diagnosis of AID and improves the prognosis of subsequent pregnancies. All patients presented at the multidisciplinary board meeting (MBM) "Thrombophilia and Pregnancy", whose ANA were discovered after an obstetrical complication, were included in a multicenter descriptive study. All patients were referred to an internal medicine consultation for diagnosis. Data were collected retrospectively by computer chart analysis and updated by phone. A total of 404 patients were included, of which 50 (12.4 %) had a diagnosis of AID related to ANA. Patients with AID had higher ANA levels (p < 0.001), with more frequent specificity (26%, versus 6.7%, p < 0.0001), and more often persistent (84% versus 30.8%, p < 0.0001) compared to patients without AID. Subsequent pregnancy outcomes were not significantly affected by ANA levels and AID diagnoses. Our study shows that the discovery of ANA after obstetrical complications may lead to an early diagnosis of AID. It makes us reconsider the systematic determination of ANA after an obstetrical event because in the case where ANA are found positive, an adapted follow-up would reduce the negative impact of ANA presence on subsequent pregnancies., (Copyright © 2021 Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
38. Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue.
- Author
-
Arcani R, Colle J, Cauchois R, Koubi M, Jarrot PA, Jean R, Boyer A, Lachamp J, Tichadou A, Couderc AL, Farnault L, Costello R, Venton G, and Kaplanski G
- Subjects
- Adult, Aged, Aged, 80 and over, COVID-19 therapy, COVID-19 virology, Cardiovascular Diseases epidemiology, Comorbidity, Diabetes Mellitus epidemiology, Female, Hospital Mortality, Humans, Male, Malnutrition epidemiology, Middle Aged, SARS-CoV-2 isolation & purification, Smoking epidemiology, Treatment Outcome, Viral Load, COVID-19 epidemiology, Hematologic Neoplasms epidemiology, Leukemia epidemiology, Lymphoma epidemiology, Multiple Myeloma epidemiology, SARS-CoV-2 pathogenicity
- Abstract
Specificities of COVID-19 disease course in patients with haematologic malignancies are still poorly studied. So, we aimed to compare patients with haematologic malignancies to patients without malignancies, matched by sex and age and hospitalised for COVID-19 at the same time and in the same centre. Among 25 patients with haematologic malignancies, we found that mortality (40% versus 4%, p < 0.01), number of days with RT-PCR positivity (21.2 ± 15.9 days [range, 3-57] versus 7.4 ± 5.6 days [range, 1-24], p < 0.01), maximal viral load (mean minimal Ct, 17.2 ± 5.2 [range, 10-30] versus 26.5 ± 5.1 [range, 15-33], p < 0.0001) and the delay between symptom onset and clinical worsening (mean time duration between symptom onset and first day of maximum requirement in inspired oxygen fraction, 14.3 ± 10.7 days versus 9.6 ± 3.7 days, p = 0.0485) were higher than in other patients. COVID-19 course in patients with haematologic malignancies has a delayed onset and is more severe with a higher mortality, and patients may be considered as super-spreaders. Clinicians and intensivists need to be trained to understand the specificity of COVID-19 courses in patients with haematological malignancies., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
39. Anti-NuMA antibodies: clinical associations and significance in patients with primary Sjögren's syndrome or systemic lupus erythematosus.
- Author
-
Arcani R, Bertin D, Bardin N, Mazodier K, Jean R, Suchon P, Venton G, Daumas A, Jean E, Villani P, Kaplanski G, and Jarrot PA
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Biomarkers blood, Child, Child, Preschool, Female, Humans, Infant, Lupus Erythematosus, Systemic blood, Male, Middle Aged, Retrospective Studies, Sjogren's Syndrome blood, Young Adult, Autoantibodies blood, Cell Cycle Proteins immunology, Lupus Erythematosus, Systemic immunology, Sjogren's Syndrome immunology
- Abstract
Objective: To determine the clinical significance of anti-nuclear mitotic apparatus (NuMA) antibodies (AC-26 or AC-25) in patients with primary Sjögren's syndrome (pSS) and SLE., Methods: Between 2013 and 2018, clinical and immunological features of pSS and SLE patients with anti-NuMA antibodies were compared with anti-NuMA antibodies-negative pSS and SLE cohorts., Results: Among 31 284 sera positive for antinuclear antibodies, 90 patients (0.29%) had anti-AC-26 (anti-NuMA1) and AC-25 (anti-HsEg5) antibodies (73.3% and 26.7%, respectively). Autoimmune diseases, mainly consisting in pSS (28.9%) and SLE (21.1%), were found in 67.8%. Anti-NuMA antibodies represented the unique ANA in 60% and 50% of patients with pSS and SLE patients, respectively. Compared with 137 anti-NuMA-negative pSS patients, 20 anti-NuMA-positive pSS presented with less frequent ocular sicca syndrome (70.0% vs 89.1%, P=0.031), dryness complications (15.0% vs 39.4%, P=0.045), or detectable anti-SSa and/or anti-SSb antibodies (40.0% vs 66.4%, P=0.027). Compared with 80 anti-NuMA-negative SLE patients, 14 anti-NuMA-positive SLE patients had no lupus nephritis (0.0% vs 28.8%, P=0.049), less frequent dsDNA antibodies (42.9% vs 75.0%, P=0.025) and complement consumption (21.4% vs 53.8%, P=0.040). Anti-NuMA-positive pSS and SLE patients less frequently required treatments compared with anti-NuMA-negative patients., Conclusion: Although rare, anti-NuMA antibodies are mainly associated with pSS and SLE and may be useful for diagnosis when other auto-antibodies are negative. PSS and SLE patients with anti-NuMA antibodies have less severe clinical and biological profiles, suggesting that anti-NuMA antibodies may constitute a good prognosis marker in both autoimmune diseases., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
40. Factors Associated With COVID-19 Hospitalizations and Deaths in French Nursing Homes.
- Author
-
Couderc AL, Correard F, Hamidou Z, Nouguerede E, Arcani R, Weiland J, Courcier A, Caunes P, Clot-Faybesse P, Gil P, Berard C, Miola C, Berbis J, Villani P, and Daumas A
- Subjects
- Aged, 80 and over, Cohort Studies, Female, Hospitalization, Humans, Male, Nursing Homes, Retrospective Studies, SARS-CoV-2, COVID-19
- Abstract
Objectives: To describe the clinical characteristics and management of residents in French nursing homes with suspected or confirmed coronavirus disease 2019 (COVID-19) and to determine the risk factors for COVID-19-related hospitalization and death in this population., Design: A retrospective multicenter cohort study., Setting and Participants: Four hundred eighty nursing home residents with suspected or confirmed COVID-19 between March 1 and May 20, 2020, were enrolled and followed until June 2, 2020, in 15 nursing homes in Marseille's greater metropolitan area., Methods: Demographic, clinical, laboratory, treatment type, and clinical outcome data were collected from patients' medical records. Multivariable analysis was used to determine factors associated with COVID-19-related hospitalization and death. For the former, the competing risk analysis-based on Fine and Gray's model-took death into account., Results: A total of 480 residents were included. Median age was 88 years (IQR 80-93), and 330 residents were women. A total of 371 residents were symptomatic (77.3%), the most common symptoms being asthenia (47.9%), fever or hypothermia (48.1%), and dyspnea (35.6%). One hundred twenty-three patients (25.6%) were hospitalized and 96 (20%) died. Male gender [specific hazard ratio (sHR) 1.63, 95% confidence interval (CI) 1.12-2.35], diabetes (sHR 1.69, 95% CI 1.15-2.50), an altered level of consciousness (sHR 2.36, 95% CI 1.40-3.98), and dyspnea (sHR 1.69, 95% CI 1.09-2.62) were all associated with a greater risk of COVID-19-related hospitalization. Male gender [odds ratio (OR) 6.63, 95% CI 1.04-42.39], thermal dysregulation (OR 2.64, 95% CI 1.60-4.38), falls (2.21 95% CI 1.02-4.75), and being aged >85 years (OR 2.36, 95% CI 1.32-4.24) were all associated with increased COVID-19-related mortality risk, whereas polymedication (OR 0.46, 95% CI 0.27-0.77) and preventive anticoagulation (OR 0.46, 95% CI 0.27-0.79) were protective prognostic factors., Conclusions and Implications: Male gender, being aged >85 years old, diabetes, dyspnea, thermal dysregulation, an altered level of consciousness, and falls must all be considered when identifying and protecting nursing home residents who are at greatest risk of COVID-19-related hospitalization and death., (Copyright © 2021 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
41. Drug-Drug Interactions in Patients with COVID-19 in Nursing Homes.
- Author
-
Correard F, Couderc AL, Arcani R, Weiland J, Courcier A, Berard C, Miola C, Berbis J, Villani P, and Daumas A
- Subjects
- Drug Interactions, Humans, Nursing Homes, SARS-CoV-2, COVID-19, Pharmaceutical Preparations
- Published
- 2021
- Full Text
- View/download PDF
42. Axial Articular Manifestations in Primary Sjögren Syndrome: Association With Spondyloarthritis.
- Author
-
Jarrot PA, Arcani R, Darmon O, Roudier J, Cauchois R, Mazodier K, Jean R, Balandraud N, and Kaplanski G
- Subjects
- Adolescent, Adult, Aged, Female, HLA-B27 Antigen, Humans, Male, Middle Aged, Young Adult, Sacroiliitis, Sjogren's Syndrome complications, Sjogren's Syndrome epidemiology, Spondylarthritis complications, Spondylarthritis epidemiology, Spondylitis, Ankylosing complications, Spondylitis, Ankylosing epidemiology
- Abstract
Objective: To assess the prevalence of axial articular manifestations (AAMs) in patients with primary Sjögren syndrome (pSS), to investigate whether these symptoms reveal an associated spondyloarthritis (SpA), and to assess their therapeutic management., Methods: Among 148 consecutive patients with pSS fulfilling European League Against Rheumatism (EULAR)/American College of Rheumatology 2019 classification criteria followed between 2010 and 2018, we selected those who presented with AAMs. The association with SpA was retained when patients fulfilled Assessment of SpA international Society criteria., Results: A total of 29 patients (20%, 28 women) with a median age of 43 years (range 15-65 yrs), were identified. The main extraglandular features were peripheral arthralgia and arthritis in 93% and 90% of patients, respectively. Positive anti-Ro/SSA (anti-SSA) antibody was reported in 62%. AAMs were inaugural in 7%, delayed from the diagnostic of pSS in 7%, and occurred concomitantly in 86% of patients. AAMs were not associated to multisystemic involvement of pSS. Radiographic sacroiliitis was mentioned in 65%, and HLA-B27 was positive in 13%. The diagnosis of SpA was retained in 23/29 patients (79%), among which 74% and 26% fulfilled psoriatic arthritis and ankylosing spondylitis criteria, respectively. There was no phenotypic difference according to the anti-SSA antibody status. With a median follow-up of 60 months (range: 5-96), 61% of patients with associated SpA required biotherapies, mainly of anti-tumor necrosis factor-α or anti-interleukin 17A molecules with a good clinical outcome in 64% and no effect on pSS., Conclusion: AAMs are not uncommon in patients with pSS and may reveal an associated SpA. Treatment of AAMs, especially when clearly associated with SpA, may necessitate biologics, following SpA-management therapeutic guidelines., (Copyright © 2021 by the Journal of Rheumatology.)
- Published
- 2021
- Full Text
- View/download PDF
43. Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection in a Patient With Waldenstrom Macroglobulinemia.
- Author
-
Velier M, Priet S, Appay R, Atieh T, Lepidi H, Kaplanski G, Jarrot PA, Koubi M, Costello R, Dignat-George F, de Lamballerie X, Tichadou A, Arcani R, Couderc AL, Touati J, Varoquaux A, Berda-Haddad Y, and Venton G
- Subjects
- Bone Marrow pathology, COVID-19 pathology, COVID-19 virology, Fatal Outcome, Female, Humans, Middle Aged, Pancytopenia pathology, Pancytopenia virology, SARS-CoV-2 isolation & purification, Waldenstrom Macroglobulinemia pathology, Waldenstrom Macroglobulinemia virology, Bone Marrow virology, COVID-19 complications, Pancytopenia etiology, SARS-CoV-2 pathogenicity, Waldenstrom Macroglobulinemia complications
- Published
- 2021
- Full Text
- View/download PDF
44. High Serum Vitamin B12 Levels Associated with C-Reactive Protein in Older Patients with Cancer.
- Author
-
Couderc AL, Puchades E, Villani P, Arcani R, Farnault L, Daumas A, Courcier A, Greillier L, Barlesi F, Duffaud F, Salas S, Costello R, Gentile G, Pradel V, Suchon P, and Venton G
- Subjects
- Activities of Daily Living, Aged, Aged, 80 and over, Geriatric Assessment, Hospitalization, Humans, Vitamin B 12, C-Reactive Protein, Neoplasms
- Abstract
Background: A Comprehensive Geriatric Assessment (CGA) has been proposed to assess prognosis and to adapt oncological care in older patients with cancer. However, few biological markers are incorporated in the CGA., Methods: This comparative study on older patients with cancer was realized before final therapeutic decision and during a CGA that included biological markers. Our objective study was to know if the serum vitamin B12-C-reactive protein index (BCI) can help to estimate early death and unplanned hospitalization. Associations between BCI and unplanned hospitalization or mortality were analyzed using ordered multivariate logistic regression., Findings: We included 621 older cancer adults in outpatient care with a median age of 81 years (range, 70-98 years) from September 2015 to May 2018. In this study, 5.6% of patients died within 3 months, 8.8% had unplanned hospitalization within 1 month, and 11.4% had unplanned hospitalization within 3 months. Hypercobalaminemia was present in 83 patients (13.4%), and 34 patients (5.5%) had BCI >40,000. According to the multivariate analysis, BCI was a prognostic factor of mortality within 3 months and unplanned hospitalizations at 1 and 3 months. Impaired activities of daily living (ADL) and palliative care were also risk factors for mortality within 3 months. Impaired instrumental ADL, low albumin level, and palliative care were risk factors for unplanned hospitalization at 1 month., Interpretation: BCI could be routinely added to the CGA process, as part of a pretreatment workup, in order to assess more precisely the frailties and to adapt oncological care in older patients treated for cancer., Implications for Practice: Aging comes with an increase of frailties and comorbidities. To identify frailties in older patients with cancer, this study used a Comprehensive Geriatric Assessment, which allowed for the adaptation of each treatment plan in accordance with the individual needs of the patients. However, biological characteristics were not included in this assessment. This study showed that hypercobalaminemia and vitamin B12 -C-reactive protein index may be potential markers for cancer with poor prognosis, particularly in the older population. These biological markers can be used in geriatric oncology and general medicine., (© 2020 AlphaMed Press.)
- Published
- 2020
- Full Text
- View/download PDF
45. Views of Medical Examiners and Psychiatrists on the Compatibility of the Mental State with Detention in Police Custody in Marseille University Hospital.
- Author
-
Houcinat M, Arcani R, Jouve E, Poinso F, Piercecchi MD, and Guivarch J
- Subjects
- Adult, Female, Forensic Psychiatry, France, Hospitals, University, Humans, Involuntary Commitment, Male, Mental Disorders diagnosis, Police, Surveys and Questionnaires, Attitude of Health Personnel, Coroners and Medical Examiners, Prisoners, Psychiatry
- Abstract
Police custody is detention in response to a suspicion of crime. A person in custody has the right to be examined by a physician, who is responsible for determining whether the person's medical condition allows him/her to continue to be held in detention. However, there is no consensus on the definition of compatibility of the mental state with custody. Our objective was to determine the relevant criteria for compatibility and incompatibility of the mental state with detention in police custody according to medical examiners and psychiatrists. A descriptive study using a semi-structured questionnaire was conducted from November 2016 to May 2017 with medical examiners and psychiatrists who examined detainees in police custody in Marseille. We recruited 17 medical examiners and 43 psychiatrists. We identified three sets of criteria used to determine a mental state compatible with custody: care, pathology/disorder, and the context of police custody. The primary determinant of incompatibility was a need for immediate hospitalization, followed by a high suicide risk, psychiatric dangerousness, delusional symptomatology, an inability to understand questions, and an inability for the detainee to defend him-/herself. The psychiatrists and medical examiners differed significantly in their views of suicide risk, delusional symptomatology, and psychiatric diagnosis. Our work has permitted identification of the main determinants of incompatibility of the mental state with custody according to psychiatrists and medical examiners in Marseille. It offers preliminary results to reach a consensus and provide an inventory for physicians to use regarding police custody., (© 2020 American Academy of Forensic Sciences.)
- Published
- 2020
- Full Text
- View/download PDF
46. A Case of Subacute Thyroiditis Associated with Erythrovirus B19 Infection.
- Author
-
Chiaruzzi M, Arcani R, Mazodier K, Jean R, Weiller PJ, Kaplanski G, and Jarrot PA
- Subjects
- Adult, Antibodies, Viral blood, DNA, Viral blood, Humans, Male, Parvoviridae Infections blood, Polymerase Chain Reaction, Radionuclide Imaging, Thyroiditis, Subacute blood, Thyroiditis, Subacute virology, Parvoviridae Infections diagnosis, Parvovirus B19, Human, Thyroiditis, Subacute diagnosis
- Published
- 2020
- Full Text
- View/download PDF
47. Anti-glutamic acid decarboxylase antibody paraneoplastic limbic encephalitis associated with Acute Myeloid Leukemia.
- Author
-
Arcani R, Jean E, Pozzo Di Borgo J, Lamarchi JF, Venton G, and Veit V
- Subjects
- Aged, Autoantibodies cerebrospinal fluid, Female, Humans, Leukemia, Myeloid, Acute complications, Limbic Encephalitis etiology, Limbic Encephalitis immunology, Limbic Encephalitis physiopathology, Magnetic Resonance Imaging, Positron-Emission Tomography, Autoantibodies immunology, Glutamate Decarboxylase immunology, Leukemia, Myeloid, Acute diagnosis, Limbic Encephalitis diagnosis
- Abstract
A 75-year-old woman developed a frontal lobe disorder a few days after the diagnostic of an Acute Myeloid Leukemia secondary to a myelodysplastic syndrome. The patterns on the cerebral Magnetic Resonance Imaging and positron emission tomography and the find of antiglutamic acid decarboxylase antibody on cerebral spinal fluid were in favor of a paraneoplastic limbic encephalitis. In cerebral spinal fluid, there were no micro-organisms nor leukemic cells. We found no sign of cancer on full body computerized tomography-scan, on full-body PET and on rectosigmoidoscopy. The patient was treated by corticosteroid and intravenous immunoglobulins with success, but she died before receiving chemotherapy. It's known that anti- glutamic acid decarboxylase antibody is involved in paraneoplastic syndromes. Paraneoplastic limbic encephalitis is frequently associated with carcinoma or Hodgkin's lymphoma, but it was only reported associated with Acute Myeloid Leukemia in one case report. Even if Acute Myeloid Leukemia is not frequently associated with paraneoplastic limbic encephalitis, the clinicians must consider paraneoplastic limbic encephalitis as an etiology of unexplained neurological disorders., Competing Interests: Declaration of Competing Interest The authors declare no conflict of interest., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
48. Efficacy of intravenous iron therapy in non-anaemic iron-deficient patients with fatigue.
- Author
-
Arcani R, Suchon P, Venton G, Soubrier C, Gaigne L, Doddoli S, Koubi M, Brandejsky L, Swiader L, Veit V, Jean E, Harlé JR, and Durand JM
- Subjects
- Administration, Intravenous, Adolescent, Adult, Aged, Aged, 80 and over, Child, Fatigue complications, Female, Humans, Iron administration & dosage, Male, Middle Aged, Treatment Outcome, Young Adult, Fatigue drug therapy, Iron pharmacology, Iron Deficiencies
- Abstract
Iron deficiency, without anaemia, is common in the general population and induces various symptoms. Its management consists of oral and intravenous supplementation for cases of inefficacy of or intolerance to oral iron. We assessed the efficacy of intravenous iron therapy in non-anaemic iron-deficient patients with fatigue. We prospectively evaluated the level of fatigue, using the Fatigue Severity Scale (FSS), in patients suffering from iron deficiency without anaemia, treated by intravenous iron at the moment of the perfusion (W0), after 4 weeks (W4), and 12 weeks (W12). Of 25 patients, at W0, the mean FFS was 49.3+/-13.7. There was a significant improvement in FSS at W4 (44+/-15; p = 0.01) and a sustained response at W12 with an FFS of 35.8+/-17.1 (p < 0,0001). There was no correlation between FSS and serum ferritin level at W12 (p=0.54) or between serum ferritin at W12 and difference between FSS at W0 and W12 (p=0.58). There were six mild adverse events (24%): asthenia (8%), nausea (8%), headache (4%), local pain (4%); and no serious adverse events. Our results suggest the rapid efficacy of intravenous iron in improving fatigue in iron deficiency without anaemia with a good profile of tolerance.
- Published
- 2020
49. [Amiodarone-induced optic neuropathy: A rare side effect].
- Author
-
Arcani R, Pellerey M, Rouby F, Gobin N, Scapin J, Chagny M, Arnould T, Ambrosi P, Gayet S, Micallef J, Villani P, and Daumas A
- Subjects
- Aged, 80 and over, Female, Humans, Iatrogenic Disease, Optic Nerve Diseases diagnosis, Papilledema chemically induced, Papilledema diagnosis, Vision Disorders chemically induced, Vision Disorders diagnosis, Visual Acuity drug effects, Amiodarone adverse effects, Anti-Arrhythmia Agents adverse effects, Optic Nerve Diseases chemically induced
- Abstract
Introduction: The diagnosis of bilateral papilledema implies emergency medical care to look for intracranial hypertension and arteritic ischemic neuropathy. However, other causes must also be mentioned, including drugs. Too often underrated because of their usual benignity, drug side ophthalmological effects can be severe and are typically bilateral., Case Report: An 80-year-old woman was hospitalized for bilateral papilledema, predominantly in the left eye, with lowered visual acuity. After ruling out intracranial hypertension, arteritic ischemic optic neuropathy, non-arteritic, and inflammatory bilateral papilledema, the diagnosis was toxic optic neuropathy., Conclusion: Bilateral edematous optic neuropathy is a known side effect of amiodarone, uncommon but to be known because of the large number of patients benefiting from this treatment., (Copyright © 2019 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
50. Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients.
- Author
-
Venton G, Turcanu M, Colle J, Thuny F, Chebrek S, Farnault L, Mercier C, Ivanov V, Fanciullino R, Suchon P, Jarrot PA, Aissi K, Roche P, Cautela J, Arcani R, and Costello R
- Subjects
- Adult, Aged, Aged, 80 and over, Cardiac Catheterization, Echocardiography, Female, Humans, Hypertension, Pulmonary diagnostic imaging, Hypertension, Pulmonary epidemiology, Male, Middle Aged, Young Adult, Bone Marrow Neoplasms complications, Hypertension, Pulmonary etiology
- Abstract
Background: Chronic myeloproliferative neoplasms (MPN) are recognized as a cause of pulmonary hypertension (pH). We ought to describe the prevalence and characteristics of PH in a cohort of MPN who were screened using transthoracic echocardiography (TTE)., Methods: One hundred eighty-three newly diagnosed consecutive MPN patients were prospectively evaluated using TTE to detect PH., Results: Two patients were diagnosed with chronic eosinophilic leukemia, two patients had post-essential thrombocythemia (ET) myelofibrosis (MF), two patients had post-polycythemia vera (PV) MF, 11 patients had primary myelofibrosis (PMF), 28 patients had chronic myeloid leukemia (CML), 51 patients had PV, and 87 patients had ET. TTE was used to determine PH, and PH was suspected in 16 of 183 patients as follows: four with PV, seven with ET, two with PMF, and three with CML. Two patients with ET were excluded because of global cardiac failure. Three patients underwent right heart catheterization to confirm PH. The 14 (7.7%) patients with PH had no cardiac or lung disease that directly involved MPN in PH development., Conclusion: In this large cohort of 183 MPN patients, TTE was used to diagnose PH, and 14 patients (7.7%) developed PH. This prevalence was lower than expected based on previously reported data, but it remains higher than in the general population., (Copyright © 2019 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.